Processing and Reporting of Breast Specimens in the Neoadjuvant Setting

Area of Science:

• Oncology
• Pathology
• Breast Cancer Research

Background:

• Accurate assessment of treatment response is crucial for managing breast cancer patients undergoing neoadjuvant therapy.
• Current methods for evaluating residual disease after neoadjuvant treatment require standardization for reproducibility.
• Multidisciplinary collaboration is key to integrating diverse findings in treatment response evaluation.

Purpose of the Study:

• To establish standardized pathological evaluation methods for residual disease in breast and lymph nodes post-neoadjuvant treatment.
• To define essential elements for pathology reports irrespective of breast cancer subtype or treatment regimen.
• To introduce the residual cancer burden score as a comprehensive measure of treatment response.

Main Methods:

• Routine pathologic macroscopic and microscopic evaluation of breast and lymph node specimens.
• Correlation of clinical, imaging, gross, and microscopic findings.
• Standardized processing of post-neoadjuvant breast cancer surgical specimens.

Main Results:

• Standardized evaluation provides accurate and reproducible measures of response to neoadjuvant treatment.
• A consistent processing approach and pathology report content are applicable across different breast cancer subtypes and neoadjuvant treatments.
• The residual cancer burden score effectively incorporates response data from both the breast and lymph nodes.

Conclusions:

• Standardized pathological assessment of residual disease is essential for accurate response measurement in neoadjuvant breast cancer treatment.
• A unified approach to specimen processing and reporting simplifies evaluation regardless of treatment or subtype.
• The residual cancer burden score offers a valuable metric for assessing treatment efficacy and can be integrated with other prognostic factors.